AI in Drug Discovery — Closing the Data Loop and Combating Eroom's Law
OVERVIEWAI in drug discovery addresses Eroom's Law—the observation that pharmaceutical R&D productivity has declined despite exponential increases in R&D spending. AI systems can accelerate target identification, lead optimization, and preclinical candidate selection by processing biomedical literature and experimental data at scale. However, AI drug discovery faces a critical evidence problem: AI models trained on published biomedical data encounter publication bias, selective reporting, and irreproducible findings embedded in training data. Anthropic's acquisition of Mithril Medicine and partnerships with Bristol Myers Squibb, Divergence Labs, and other pharmaceutical companies focus on improving data quality and evidence standards in AI-driven drug development. The closing of the "data loop" involves validating AI-generated hypotheses through experimental work, then feeding experimental results back into AI training datasets. This iterative process improves AI model quality but requires substantial time and cost. Pharma companies increasingly recognize that AI's highest value emerges not from replacing traditional drug discovery but from augmenting human chemists and biologists with AI-powered hypothesis generation and lead optimization tools. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.